Penn Capital Management Company LLC Boosts Stake in Catalent, Inc. (NYSE:CTLT)

Penn Capital Management Company LLC grew its position in shares of Catalent, Inc. (NYSE:CTLTGet Rating) by 18.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 25,248 shares of the company’s stock after acquiring an additional 3,850 shares during the period. Penn Capital Management Company LLC’s holdings in Catalent were worth $2,709,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CTLT. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Catalent by 22.5% in the 2nd quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,043 shares of the company’s stock worth $326,000 after purchasing an additional 558 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Catalent by 17.7% in the 1st quarter. JPMorgan Chase & Co. now owns 4,474,419 shares of the company’s stock worth $496,212,000 after purchasing an additional 673,706 shares in the last quarter. Viking Global Investors LP boosted its position in shares of Catalent by 66.2% in the 1st quarter. Viking Global Investors LP now owns 1,893,644 shares of the company’s stock worth $210,005,000 after purchasing an additional 754,290 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its position in Catalent by 12.0% in the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 90,954 shares of the company’s stock valued at $9,759,000 after acquiring an additional 9,723 shares in the last quarter. Finally, Illinois Municipal Retirement Fund lifted its position in Catalent by 88.1% in the 2nd quarter. Illinois Municipal Retirement Fund now owns 6,028 shares of the company’s stock valued at $647,000 after acquiring an additional 2,824 shares in the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Insider Transactions at Catalent

In other news, SVP Michael J. Grippo sold 2,451 shares of the company’s stock in a transaction on Monday, October 31st. The stock was sold at an average price of $65.83, for a total value of $161,349.33. Following the completion of the sale, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Catalent news, SVP Michael J. Grippo sold 2,451 shares of the stock in a transaction on Monday, October 31st. The stock was sold at an average price of $65.83, for a total value of $161,349.33. Following the completion of the sale, the senior vice president now owns 17,792 shares in the company, valued at approximately $1,171,247.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas W. Hawkeswood sold 930 shares of the stock in a transaction on Monday, October 10th. The stock was sold at an average price of $77.46, for a total value of $72,037.80. Following the completion of the sale, the insider now owns 5,364 shares of the company’s stock, valued at approximately $415,495.44. The disclosure for this sale can be found here. Insiders sold 4,161 shares of company stock worth $273,713 in the last three months. Corporate insiders own 0.58% of the company’s stock.

Catalent Trading Down 3.6 %

NYSE:CTLT opened at $45.54 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.86 and a quick ratio of 2.08. The firm has a market capitalization of $8.20 billion, a price-to-earnings ratio of 19.46, a price-to-earnings-growth ratio of 2.09 and a beta of 1.23. Catalent, Inc. has a one year low of $40.69 and a one year high of $130.97. The business has a fifty day moving average price of $57.44 and a 200-day moving average price of $86.20.

Catalent (NYSE:CTLTGet Rating) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.25 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.24). The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a return on equity of 12.55% and a net margin of 8.83%. Sell-side analysts forecast that Catalent, Inc. will post 3.12 EPS for the current year.

Analyst Ratings Changes

CTLT has been the topic of several analyst reports. Morgan Stanley lowered their price objective on Catalent from $120.00 to $81.00 and set an “overweight” rating on the stock in a research report on Thursday, November 3rd. KeyCorp lowered their price objective on Catalent from $125.00 to $85.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 2nd. Barclays lowered their price objective on Catalent from $105.00 to $62.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 2nd. TheStreet cut Catalent from a “b-” rating to a “c+” rating in a research report on Friday, October 28th. Finally, Royal Bank of Canada lowered their price target on Catalent from $125.00 to $73.00 and set an “outperform” rating on the stock in a report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Catalent presently has a consensus rating of “Hold” and a consensus target price of $92.80.

Catalent Company Profile

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Articles

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLTGet Rating).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.